Select your timezone:
Reset

Time Room Session
08:30
09:45
08:30-09:45 Riverfront

Immunoprotection of Stem Cell Islets: Genome Editing and Beyond


Holger Russ, United States
Hypoimmunogenic stem cell islets
Holger Russ, United States
Hypoimmunogenic stem cell islets
Lorenzo Piemonti, Italy
Protection from NK mediated damage
Lorenzo Piemonti, Italy
Protection from NK mediated damage
Elad Sintov, United States
CRISPR screening to attain immunoprotection of stem cell-derived islets
Elad Sintov, United States
CRISPR screening to attain immunoprotection of stem cell-derived islets
Haval Shirwan, United States
Microgels presenting FasL as an immunomodulatory scheme to protect beta cells from rejection
Haval Shirwan, United States
Microgels presenting FasL as an immunomodulatory scheme to protect beta cells from rejection
Jeffrey Millman, United States
Panel Discussion and Q&A
Jeffrey Millman, United States
Panel Discussion and Q&A

09:45 - 10:15 |  Networking Coffee Break.         Parkview & Somerset

10:15
11:30
10:15-11:30 Riverfront

The Islet Product, Planning for Trials, and Manufacturing


Yasaman Aghazadeh, Canada
Recapitulating the vascular niche to improve beta cell replacement therapies for T1D
Yasaman Aghazadeh, Canada
Recapitulating the vascular niche to improve beta cell replacement therapies for T1D
William Rust, United States
Stem cell-derived islets for treating diabetes: The Seraxis approach
William Rust, United States
Stem cell-derived islets for treating diabetes: The Seraxis approach
Jerome Ritz, United States
Planning for clinical trials: Lessons learned from autologous iPSC-derived products
Jerome Ritz, United States
Planning for clinical trials: Lessons learned from autologous iPSC-derived products
Tom Bollenbach, United States
Scale - up manufacturing; how to do it or not so easy?
Tom Bollenbach, United States
Scale - up manufacturing; how to do it or not so easy?
James Markmann, United States
Panel Discussion and Q&A
James Markmann, United States
Panel Discussion and Q&A

11:30 - 11:45 |  Break         Parkview & Somerset

11:45
12:30
11:45-12:30 Riverfront

Panel Discussion: Eligibility Criteria Considerations for Stem Cell Trials in Diabetes


Patricia Beaston, United States
Panelist
Patricia Beaston, United States
Panelist
Yohannes Haile, Canada
Panelist
Yohannes Haile, Canada
Panelist
Bruce Perkins, Canada
Panelist
Bruce Perkins, Canada
Panelist
Thierry Berney, Switzerland
Panelist
Thierry Berney, Switzerland
Panelist
Michael R Rickels, United States
Panelist
Michael R Rickels, United States
Panelist
12:30
12:45
12:30-12:45 Riverfront

Closing Remarks


Organized by

A section of


© 2024 BetaCells 2023